€0.51
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Defence Therapeutics Inc.
sharewise wants to provide you with the best news and tools for Defence Therapeutics Inc., so we directly link to the best financial data sources.
Financials
News
Defence Therapeutics Demonstrates Strong Preclinical In Vivo Efficacy Results Evaluation Accum-Kadcyla in Breast Cancer Models
Montreal, QC, Canada, November 4th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, QC, Canada, December 4th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, QC, Canada, December 4th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using its Proprietary Accum Technology
Montreal, QC, Canada, November 19th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”),
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, QC, Canada, November 6th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”),
Defence to Present New Scientific Data on its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Montreal, QC, Canada, October 23rd, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Montreal, QC, Canada, October 6th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Montreal, QC, Canada, October 2nd, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics Appoints Dr. Amie Phinney as Director
Montreal, QC, Canada, September 16th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
Montreal, QC, Canada, September 2nd, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”) (CSE: DTC) (FSE: DTC) (USOTC: DTCFF), a leading biotechnology company specialized in drug